Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
30.99-0.02 (-0.06%)
As of 2:33 PM EDT. Market open.
People also watch:
NVSSNYNSRGYAZNBAYRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open30.89
Prev Close31.01
Bid0.00 x
Ask0.00 x
Day's Range30.80 - 31.05
52wk Range29.89 - 35.13
1y Target EstN/A
Market Cap212.09B
P/E Ratio (ttm)22.80
Beta0.66
Volume695,923
Avg Vol (3m)899,603
Dividend & Yield1.02 (3.22%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone
    Investor's Business Daily35 minutes ago

    Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone

    Regeneron fell after a combo therapy with Eylea for treating wet age-related macular degeneration performed worse than Eylea alone. Ophthotech also tumbled.

  • Celgene's Trio Of New Drugs Could Tack On $3 Billion-Plus: RBC
    Investor's Business Daily1 hour ago

    Celgene's Trio Of New Drugs Could Tack On $3 Billion-Plus: RBC

    Celgene stock lifted Friday after unveiling drugs in testing that could tack on $3 billion to $4 billion in sales, RBC says.

  • PR Newswireyesterday

    Harmony® Prenatal Test for assessment of Down syndrome and other chromosomal disorders receives CE mark

    OTCQX:RHHBY) today announced that the Harmony Prenatal Test for assessing the probability of Down syndrome (Trisomy 21) and other chromosomal disorders has received the CE mark. This enables laboratories to perform local in vitro diagnostic (IVD) testing in countries that accept the mandatory conformity marking.  Local testing availability permits laboratories to comply with reimbursement requirements and expedite test results for healthcare providers and expectant parents in their regions. "This is exceptionally good news as CE marking of the Harmony Prenatal Test will make highly accurate cfDNA testing accessible to a wider spectrum of pregnant women," said Professor Kypros Nicolaides, M.D., director of the Fetal Medicine Foundation and the Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in London.